AI-guided echocardiogram screening for cardiac amyloidosis
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases
This study is testing whether an AI tool can help doctors find people at high risk for cardiac amyloidosis by analyzing heart ultrasound images more accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cedars-Sinai Medical Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT05139797 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of an artificial intelligence algorithm, EchoNet-LVH, in identifying patients at high risk for cardiac amyloidosis through echocardiographic screening. The study aims to enhance the accuracy of cardiac disease diagnosis by leveraging machine learning techniques to detect features that may be overlooked by human experts. By improving the identification of cardiac hypertrophy, the study seeks to facilitate timely and appropriate treatment for patients who may benefit from further screening. The approach addresses the limitations of traditional echocardiography, which can be subjective and variable among providers.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a high suspicion of cardiac amyloidosis as determined by the AI algorithm.
Not a fit: Patients who decline to be seen at the specialty clinic or those who have passed away will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely diagnoses of cardiac amyloidosis, improving patient outcomes through targeted therapies.
How similar studies have performed: Other studies have shown promise in using AI for diagnostic purposes in cardiology, suggesting that this approach may yield successful outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who have a high suspicion for cardiac amyloidosis by AI algorithm Exclusion Criteria: * Patients who decline to be seen at specialty clinic * Patients who have passed away
Where this trial is running
Los Angeles, California
- Cedars-Sinai Medical Centre (Los Angeles) — Los Angeles, California, United States (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.